Cargando…

Thrombopoietin receptor agonist antibody for treating chemotherapy-induced thrombocytopenia

BACKGROUND: Thrombocytopenia is a common complication in cancer patients undergoing chemotherapy. Chemotherapy-induced thrombocytopenia (CIT) leads to dose reduction and treatment delays, lowering chemotherapy efficacy and survival rate. Thus, rapid recovery and continuous maintenance of platelet co...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shin, Jiwon, Kim, Min-Jung, Quan, Xingguo, Kim, Ji Woong, Lee, Sukmook, Park, SaeGwang, Jeong, Jee-Yeong, Yea, Kyungmoo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10230746/ https://www.ncbi.nlm.nih.gov/pubmed/37259024 http://dx.doi.org/10.1186/s12885-023-10975-3

Ejemplares similares

Role of Thrombopoietin Receptor Agonists in Inherited Thrombocytopenia
por: Bastida, José María, et al.
Publicado: (2021)

Use of Thrombopoietin Receptor Agonists in Childhood Immune Thrombocytopenia
por: Garzon, Angelica Maria, et al.
Publicado: (2015)

Optimal use of thrombopoietin receptor agonists in immune thrombocytopenia
por: Al-Samkari, Hanny, et al.
Publicado: (2019)

Thrombocytopenia and Procedural Prophylaxis in the Era of Thrombopoietin Receptor Agonists
por: Nilles, Kathy M., et al.
Publicado: (2019)

Thrombopoietin Receptor Agonists for Thrombocytopenia Secondary to HER2-Targeted Antibody Drug Conjugates
por: Rainone, Michael, et al.
Publicado: (2023)

Efficacy and safety of thrombopoietin receptor agonists in solid tumors with chemotherapy-induced thrombocytopenia: a meta-analysis
por: Chen, Wen, et al.
Publicado: (2023)

Switching thrombopoietin receptor agonist treatments in patients with primary immune thrombocytopenia
por: González-Porras, José R., et al.
Publicado: (2019)

Thrombopoietin Receptor Agonists: Can These Be the Future Answer to the Deadly Thrombocytopenia in Dengue Fever?
por: Roy, Sayak
Publicado: (2019)

Thrombopoietin receptor agonist for treatment of immune thrombocytopenia in pregnancy: a narrative review
por: Agarwal, Nikki, et al.
Publicado: (2021)

Prolonged thrombocytopenia after CAR T-cell therapy: the role of thrombopoietin receptor agonists
por: Drillet, Gaëlle, et al.
Publicado: (2022)

P1666: EFFECT OF AGONISTS TO THROMBOPOIETIN RECEPTORS ON PLATELET GLYCOME OF PATIENTS WITH IMMUNE THROMBOCYTOPENIA
por: Monzón Manzano, E., et al.
Publicado: (2022)

Successful Treatment with Thrombopoietin Receptor Agonist in Avoiding Splenectomy for Patients with Chronic Refractory Immune Thrombocytopenia
por: Khalafallah, Alhossain, et al.
Publicado: (2012)

Efficacy and safety of thrombopoietin receptor agonists in children with chronic immune thrombocytopenia: a meta-analysis
por: Guo, Jian-Chun, et al.
Publicado: (2017)

Current Advance in Thrombopoietin Receptor Agonists in the Management of Thrombocytopenia Associated With Chronic Liver Disease: Focus on Avatrombopag
por: Abdela, Jemal
Publicado: (2019)

Second-line administration of thrombopoietin receptor agonists in immune thrombocytopenia: Italian Delphi-based consensus recommendations
por: Carpenedo, Monica, et al.
Publicado: (2021)

PB2626: THROMBOPOIETIN RECEPTOR AGONISTS FOR RESISTANT THROMBOCYTOPENIA IN PREGNANCY A CASE SERIES AND REVIEW OF LITERATURE
por: Sayed, Gamal, et al.
Publicado: (2023)

Cell Surface GRP94 as a Novel Emerging Therapeutic Target for Monoclonal Antibody Cancer Therapy
por: Kim, Ji Woong, et al.
Publicado: (2021)

Thrombopoietin mutation in congenital amegakaryocytic thrombocytopenia treatable with romiplostim
por: Pecci, Alessandro, et al.
Publicado: (2017)

Correction: Kim et al. Cell Surface GRP94 as a Novel Emerging Therapeutic Target for Monoclonal Antibody Cancer Therapy. Cells 2021, 10, 670
por: Kim, Ji Woong, et al.
Publicado: (2021)

The Clinical Efficacy and Economic Benefits of Recombinant Human Thrombopoietin for the Treatment of Chemotherapy or Chemoradiotherapy-Induced Thrombocytopenia
por: Wang, Wenxian, et al.
Publicado: (2022)

Efficacy and safety of thrombopoietin receptor agonists in patients with primary immune thrombocytopenia: A systematic review and meta-analysis
por: Wang, Li, et al.
Publicado: (2016)

Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia
por: Jurczak, Wojciech, et al.
Publicado: (2018)

Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia
por: Lozano, Maria L., et al.
Publicado: (2019)

P1635: REAL-WORLD DATA OF THROMBOPOIETIN RECEPTOR AGONISTS (TPO-RA) USE IN IMMUNE THROMBOCYTOPENIA (ITP)
por: Dangudubiyyam, S., et al.
Publicado: (2022)

Use of thrombopoietin receptor agonists in adults with immune thrombocytopenia: a systematic review and Central European expert consensus
por: Pulanić, Dražen, et al.
Publicado: (2023)

PB2618: USE AND DISCONTINUATION OF THROMBOPOIETIN RECEPTOR AGONISTS IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA: A SINGLE CENTRE EXPERIENCE
por: Martinez, Celia, et al.
Publicado: (2023)

The non-peptide thrombopoietin receptor agonist eltrombopag stimulates megakaryopoiesis in bone marrow cells from patients with relapsed multiple myeloma
por: Jeong, Jee-Yeong, et al.
Publicado: (2015)

Thrombopoietin receptor agonists: ten years later
por: Ghanima, Waleed, et al.
Publicado: (2019)

Effect of Thrombopoietin Receptor Agonist on Pregnant Mice
por: Nakai, Kensaku, et al.
Publicado: (2022)

Icaritin Provokes Serum Thrombopoietin and Downregulates Thrombopoietin/MPL of the Bone Marrow in a Mouse Model of Immune Thrombocytopenia
por: Zhang, Ke, et al.
Publicado: (2018)

Retracted: The Clinical Efficacy and Economic Benefits of Recombinant Human Thrombopoietin for the Treatment of Chemotherapy or Chemoradiotherapy-Induced Thrombocytopenia
por: Imaging, Contrast Media & Molecular
Publicado: (2023)

The Use of Thrombopoietin Receptor Agonists for Correction of Thrombocytopenia prior to Elective Procedures in Chronic Liver Diseases: Review of Current Evidence
por: Qureshi, Kamran, et al.
Publicado: (2016)

A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopenia
por: Mei, Heng, et al.
Publicado: (2021)

Thrombopoietin receptor agonists for acquired thrombocytopenia following anti-CD19 CAR-T-cell therapy: a case report
por: Baur, Rebecca, et al.
Publicado: (2021)

P1636: PATIENT PREFERENCES AND EXPERIENCES REGARDING THROMBOPOIETIN-RECEPTOR AGONISTS FOR IMMUNE THROMBOCYTOPENIA IN THE NETHERLANDS (TRAPEZE NL STUDY).
por: Jansen, A. G., et al.
Publicado: (2022)

Cerebral venous sinus thrombosis in immune thrombocytopenia patients treated with thrombopoietin receptor agonist: Case reports and literature review
por: Teekaput, Chutithep, et al.
Publicado: (2022)

The Outcomes and Adverse Drug Patterns of Immunomodulators and Thrombopoietin Receptor Agonists in Primary Immune Thrombocytopenia Egyptian Patients with Hemorrhage Comorbidity
por: Hamed, Eman Mostafa, et al.
Publicado: (2023)

P1629: DISCONTINUATION OF TREATMENT WITH THROMBOPOIETIN RECEPTOR AGONISTS IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA: A SINGLE-CENTER CLINICAL EXPERIENCE
por: Santano, Ana María Mena, et al.
Publicado: (2023)

Nationwide Survey on the Use of Thrombopoietin Receptor Agonists (TPO-RA) for the Management of Immune Thrombocytopenia in Current Clinical Practice in Italy
por: Napolitano, Mariasanta, et al.
Publicado: (2023)

Serum Thrombopoietin and cMpl Expression in Thrombocytopenia of Different Etiologies
por: Vianello, Fabrizio, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_p3h4j0rh076970cfa5fqp6uc32